ATRA Atara Biotherapeutics Inc.

15.65
+0.10  (1%)
Previous Close 15.55
Open 15.60
Price To book 2.16
Market Cap 478255001
Shares 30,559,425
Volume 192,873
Short Ratio 22.25
Av. Daily Volume 200,443

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial planned for 2H 2017.
ATA 129 - ALLELE
Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT)
Phase 3 trial planned for 2H 2017.
ATA 129 - MATCH
Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT)
Phase 1/2 trial to be initiated 2018.
ATA129 and KEYTRUDA
Nasopharyngeal carcinoma (NPC)
Phase 2 endpoint not met December 2015
PINTA 745
Protein-energy wasting